Research programme: psoriasis therapeutics - Foamix/VIB
Latest Information Update: 06 Jun 2013
At a glance
- Originator VIB
- Developer Foamix; VIB
- Mechanism of Action Caspase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 06 Jun 2013 Discontinued for Psoriasis in Belgium (Topical)
- 04 Feb 2009 Early research in Psoriasis in Belgium (Topical)